Thursday, January 11, 2007

InteKrin Scores $23M

Palo Alto-based InteKrin Therapeutics has raised $23M in a venture financing round, the firm said today. The round was led by Sofinnova Ventures and also included Orbimed Advisors and Vivo Ventures. Prior investors Asset Management and Sears Capital Management also participated. InteKrin will use the funding for clinical development of the firm's drug candidate targeting type II diabetes. More information »